<- Go Home
Cybin Inc.
Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions.
Market Cap
$281.4M
Volume
134.3K
Cash and Equivalents
$154.3M
EBITDA
-$130.6M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$27.93
52 Week Low
$9.15
Dividend
N/A
Price / Book Value
1.10
Price / Earnings
-1.74
Price / Tangible Book Value
1.64
Enterprise Value
$127.2M
Enterprise Value / EBITDA
-0.98
Operating Income
-$130.8M
Return on Equity
-81.54%
Return on Assets
-51.09
Cash and Short Term Investments
$154.3M
Debt
$133.0K
Equity
$255.0M
Revenue
N/A
Unlevered FCF
-$51.3M
Sector
Pharmaceuticals
Category
N/A
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick Premium